Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to analyze CRM Stock & FICO stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor28 Apr 2026, 22:21 UTC
Video preview for Friends! In this video, I'm going to analyze CRM Stock & FICO stock
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
0
Canonical correct result
Failed
1
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on two stocks, FICO and Salesforce (CRM), highlighting their recent price performance and future outlook. FICO is presented as potentially undervalued with strong future growth prospects, while Salesforce is depicted as having missed its guidance and facing management issues, making it a less attractive investment. The analyst also touches upon the broader market trend of AI infrastructure stocks booming and discusses the importance of proper valuation and company fundamentals. For FICO, the target price is projected at $2279.43 based on a PE ratio of 24 and anticipated earnings growth. Salesforce, on the other hand, is seen as facing headwinds due to missed guidance and leadership concerns, leading to a bearish outlook. The company's overpayment for acquisitions and the shift towards a subscription-based revenue model are noted as potential challenges.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.